Tezspire shows clinical improvement in eosinophilic esophagitis patients

Results from the phase III CROSSING clinical trial indicate that tezepelumab (Tezspire), developed by AstraZeneca and Amgen, significantly improves histological remission and reduces dysphagia in adolescents and adults with symptomatic, uncontrolled eosinophilic esophagitis (EoE).

Presented at the United European Gastroenterology (UEG) Week 2026 in Barcelona, the study showed that at week 24, histological remission was achieved by 64.8% of patients receiving a 210 mg dose and 68.9% of those receiving a 420 mg dose, compared to 3.5% in the placebo group. These efficacy levels were maintained through week 52.

The treatment, administered subcutaneously every four weeks, also reduced the frequency and severity of dysphagia (difficulty swallowing). According to the Dysphagia Symptom Questionnaire (DSQ), the 210 mg dose saw an 18.8-point reduction and the 420 mg dose saw a 22.0-point reduction, compared to 14.7 points in the placebo group.